1,206
Participants
Start Date
November 30, 2012
Primary Completion Date
November 30, 2013
Study Completion Date
November 30, 2013
Group A: Trivalent Oral Polio Vaccine
Group A will receive 3 doses of trivalent oral polio vaccine (tOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
Group B: Bivalent Oral Polio Vaccine
Group B will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
Group C: Inactivated Polio Vaccine
Group C will receive 2 doses of inactivated polio vaccine (IPV) at 6 and 14 weeks of age. IPV will be administered intramuscularly using standard needle and syringe. A challenge dose of tOPV will be administered at 18 weeks of age.
Group D: fractional IPV (f-IPV)
Group D will receive 2 doses of fractional inactivated polio vaccine (f-IPV) at 6 and 14 weeks of age. f-IPV (one-fifth dose of IPV) will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
Arm E: f-IPV and bOPV
Group E will receive 2 doses of f-IPV at 6 and 14 weeks of age with bOPV at 10 weeks of age. f-IPV will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
Mirpur Health Clinic, Dhaka
Collaborators (1)
International Centre for Diarrhoeal Disease Research, Bangladesh
OTHER
Ministry of Health and Family Welfare, Bangladesh
UNKNOWN
NanoPass Technologies Ltd
INDUSTRY
Centers for Disease Control and Prevention
FED